<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0002" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Efficacy and Adverse Effects of Antiviral and Anti-Inflammatory Agents</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Treatment/Management</th>
    <th rowspan="1" colspan="1">Efficacy</th>
    <th rowspan="1" colspan="1">Adverse Effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">PVI irrigation</td>
    <td rowspan="1" colspan="1">Off-label use for EKC; reduces risk of disease transmission</td>
    <td rowspan="1" colspan="1">Dry eye symptoms, corneal epithelial damage/toxicity with repeated use. 
     <xref rid="CIT0104" ref-type="bibr">104</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Cidofovir</td>
    <td rowspan="1" colspan="1">Antiviral activity against HAdV5 exhibited in animal models. 
     <xref rid="CIT0105" ref-type="bibr">105</xref>
     <break/>Cidofovir 1% lowered the frequency of severe corneal opacities in patients with adenoviral keratoconjunctivitis.
     <xref rid="CIT0064" ref-type="bibr">64</xref>,
     <xref rid="CIT0106" ref-type="bibr">106</xref>
    </td>
    <td rowspan="1" colspan="1">Narrow therapeutic index when used topically; high doses for greater than one week associated with rare cases of lacrimal canalicular
     <break/>blockade in rabbit models.
     <xref rid="CIT0107" ref-type="bibr">107</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Ganciclovir</td>
    <td rowspan="1" colspan="1">3% ganciclovir reduced HAdV 5 replication and pathogenesis in animal models.
     <xref rid="CIT0108" ref-type="bibr">108</xref> Ganciclovir is efficacious against HAdV types that cause EKC.
     <xref rid="CIT0046" ref-type="bibr">46</xref> Ganciclovir ophthalmic gel treatment prevents complications in adenoviral ocular infection. 
     <xref rid="CIT0109" ref-type="bibr">109</xref>
    </td>
    <td rowspan="1" colspan="1">Transient blur following instillation, eye irritation, punctate keratitis, conjunctival hyperemia.
     <xref rid="CIT0108" ref-type="bibr">108</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Brincidofovir</td>
    <td rowspan="1" colspan="1">Brincidofovir has antiviral activity against adenoviruses. 
     <xref rid="CIT0055" ref-type="bibr">55</xref>, 
     <xref rid="CIT0105" ref-type="bibr">105</xref>, 
     <xref rid="CIT0110" ref-type="bibr">110</xref>–
     <xref rid="CIT0113" ref-type="bibr">113</xref> 
    </td>
    <td rowspan="1" colspan="1">Mild gastrointestinal tract upset, asymptomatic and elevated levels of serum transaminases
     <xref rid="CIT0114" ref-type="bibr">114</xref> diarrhea, acute graft versus host disease, abdominal pain, nausea/vomiting, decreased appetite, peripheral edema, hyperglycemia, hypokalemia, rash, fatigue, fever.
     <xref rid="CIT0115" ref-type="bibr">115</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Topical corticosteroids</td>
    <td rowspan="1" colspan="1">Relief of EKC symptoms and Persistent adenoviral SEIs.
     <xref rid="CIT0002" ref-type="bibr">2</xref>,
     <xref rid="CIT0063" ref-type="bibr">63</xref> 
    </td>
    <td rowspan="1" colspan="1">Glaucoma and cataracts.
     <xref rid="CIT0116" ref-type="bibr">116</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Topical cyclosporine</td>
    <td rowspan="1" colspan="1">Effective against persistent adenoviral SEIs.
     <xref rid="CIT0066" ref-type="bibr">66</xref>,
     <xref rid="CIT0069" ref-type="bibr">69</xref>,
     <xref rid="CIT0117" ref-type="bibr">117</xref>–
     <xref rid="CIT0119" ref-type="bibr">119</xref>
    </td>
    <td rowspan="1" colspan="1">Transient or long-lasting burning sensation;
     <xref rid="CIT0120" ref-type="bibr">120</xref> ocular pain/irritation, redness; eyelid swelling in Steven Johnsons patients.
     <xref rid="CIT0121" ref-type="bibr">121</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Topical tacrolimus</td>
    <td rowspan="1" colspan="1">Superior to dexamethasone in reducing symptomology and SEIs
     <xref rid="CIT0070" ref-type="bibr">70</xref> as well as a safe and effective treatment of adenoviral SEIs.
     <xref rid="CIT0087" ref-type="bibr">87</xref>,
     <xref rid="CIT0122" ref-type="bibr">122</xref>,
     <xref rid="CIT0123" ref-type="bibr">123</xref>
    </td>
    <td rowspan="1" colspan="1">Transient burning sensation.
     <xref rid="CIT0124" ref-type="bibr">124</xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
